Haha, omg! As if ANYONE in the industry would want "competitive market monitoring" data on Nephron. This is so delusional on so many levels... And, 9/10 odds this is another drunken post by the CEO (10:36PM Sunday night... numerous derogatory and demeaning statements...we all know how she treats everyone so the author of this should be obvious) If she didn't have Bill's money behind her, wonder what she would be??? God, I feel sorry for that awesome old dude, lesson learned that one mistake can ruin decades of success.
Dude, wake up. You don't think our major brand competitors monitor Nephrons every move too? They hire outside pawns to do the grunt research. Get your head out of the sand dude.
Asthma/COPD Portfolio Strategy Partner | Strategic Insights Manager - Customer and Business Insights
GlaxoSmithKline
o Lead for COPD Portfolio Strategy. Primary responsibility for Respiratory portfolio-level strategy, articulating a broader customer-focused vision that bridges between in-line and new product development in order to provide cross-functional leadership across disease states (Asthma/COPD) as well as brands (Advair, Flovent, Serevent, Ventolin).
o Lead Strategic Insights Manager for key COPD launch assets Anoro and Umeclidinium, where I play a critical role in the development of the core launch strategy - segmentation, positioning, targeting, pricing/payer, core messaging, etc. Responsible for US Respiratory Competitive Intelligence.
o Core member of several strategic teams, global and domestic, dealing with current market issues and products in development.
o Leading efforts to effectively utilize emerging data sets, specifically patient-level data
o Specific project work in this and past positions includes consumer/professional positioning and message/creative development, segmentation, forecasting, epidemiology, market evaluation, exploration of strategic opportunities, competitive intelligence, linguistics/ethnographic research, brand equity, and market tracking.